Literature DB >> 222663

Lack of effect of antiserotoninergic and/or dopaminergic treatment in patients with pituitary-dependent Cushing's syndrome.

B Ambrosi, M Gaggini, F Secchi, G Faglia.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222663     DOI: 10.1055/s-0028-1095778

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


× No keyword cloud information.
  7 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

2.  Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.

Authors:  A B Atkinson; A L Kennedy; B Sheridan
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  Medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

5.  Long term bromocriptine therapy in Cushing's disease.

Authors:  L P Kapcala; I M Jackson
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

6.  Effect of short and long-term administration of lisuride in Cushing's disease.

Authors:  M Boscaro; G Merola; E Serafini; F Mantero
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

7.  Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.